Kelley awarded ARRA grant on â€œThe Role of Ape1 in Neurotoxicity of Cancer Treatments"
INDIANAPOLIS -- Mark R. Kelley, PhD, Betty and Earl Herr Professor of Pediatric Oncology, Department of Pediatrics, IUSM, was awarded a $358,757 grant under the American Recovery and Reinvestment Act of 2009, from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. The two-year grant will cover research on how DNA repair mechanisms are involved in neurotoxicity during cancer treatments commonly referred to as “chemobrain.”
Kelley is Associate Director at the Herman B Wells Center for Pediatric Research and Associate Director for Basic Science Research at the IU Simon Cancer Center. His pediatric hematology/oncology research group and lab focus on the role a pivotal DNA repair enzyme plays as a therapeutic target for a variety of cancers such as pediatric and adult brain tumors, pancreatic, ovarian and other cancers. The studies funded by this stimulus money will continue work he has been doing with his collaborator, Dr. Michael Vasko, Pharmacology/Toxicology, to understand and prevent the neurotoxic side effects of chemotherapy and radiation on both central and peripheral nervous system functions. This is a growing area of research focus at the IUSM. This grant will further this research.
The Herman B Wells Center for Pediatric Research conducts basic science and translational research within the Department of Pediatrics at the Indiana University School of Medicine, offering exceptional opportunities for collaborations not only between basic scientists and physicians, but between research centers such as the Wells Center and the IU Simon Cancer Center.
The goals of the Wells Center are to increase knowledge of the causes and mechanisms of serious pediatric diseases, to develop innovative approaches to diagnosis and treatment of childhood disease, and to provide an outstanding training environment for medical and graduate students, residents, interns and fellows.
Areas of pediatric research include immune disorders, blood-related and heart diseases, lung development, diabetes and cancer and growth disorders.
CONTACT: Colleen Kelly
317-274-8908 or 317-383-6198